Chen Chen

Chen Chen


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Advanced Composites and Hybrid Materials
Verified
Journal Article
Open access
PDF file
XFXinting Feng
Xinting Feng
Zhiwen LuoZhiwen Luo
Zhiwen Luo
HSHaojun Shi
Haojun Shi
SCShuo Chen
Shuo Chen
CCChen Chen
Chen Chen
SCShiyi Chen
Shiyi Chen
Anterior cruciate ligament (ACL) injury is one of the most common and severe sports-related knee injuries. Anterior cruciate ligament reconstruction (ACLR) is currently the primary clinical treatment. Compared with other grafts, artificial ligaments offer significant advantages in enabling early return to sports after surgery and, therefore, have been widely studied and applied in clinical practice. This review summarizes recent literature on the application of artificial ligaments in ACLR, outlining the classification of ligament materials, historical development, and advancements in biomaterial research. Although early artificial ligaments showed limited clinical efficacy, the continuous progress in materials science and tissue engineering has facilitated the use of various natural, synthetic, and composite materials in ACL artificial ligament construction, significantly improving their biocompatibility and mechanical properties. In addition, researchers have employed strategies such as surface modification, bioactive factor loading, and cell delivery to endow artificial ligaments with enhanced functionality, yielding promising results in animal studies. This review provides a comprehensive overview of the progress in artificial ligaments biomaterials, systematically summarizes the current changes and innovations in artificial ligament scaffold materials, surface modification technologies, and new auxiliary strategies and highlights auxiliary strategies used with artificial ligaments in ACLR to enhance tendon bone healing, with particular emphasis on the role of tissue engineering and biomaterials. The clinical translation prospects of these emerging strategies are also discussed.

3 April 2026 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
JMJun Ma
Jun Ma
CCChen Chen
Chen Chen
HJHao Jiang
Hao Jiang
MXMengran Xi
Mengran Xi
WLWei Luo
Wei Luo
PYPatrick Shu-Hang YUNG
Patrick Shu-Hang YUNG
Sarcopenia and osteoarthritis are two common musculoskeletal disorders that often coexist, posing significant challenges in clinical management. These conditions share underlying mechanisms such as chronic inflammation, metabolic dysfunction, and biomechanical stress, which accelerate musculoskeletal degeneration. Sarcopenia, characterized by muscle loss and weakness, and osteoarthritis, marked by cartilage degradation and joint dysfunction, frequently overlap, leading to increased disability and reduced quality of life. The presence of both conditions creates a detrimental cycle where muscle weakness exacerbates joint pain, and joint dysfunction further weakens muscles. This comorbidity complicates treatment, requiring integrated strategies that address both muscle and joint pathology. Advances in personalized therapies, driven by multi-omics technologies, are crucial in targeting these interconnected conditions more effectively. Precision medicine, using genetic, metabolic, and physiological data, can help tailor treatments and improve patient outcomes. Furthermore, the integration of adaptive interventions, digital twin models, and real-time feedback systems will play key roles in refining individualized treatment plans. Multi-omics integration and real-world evidence are also transforming how clinical trials are designed and how we assess disease progression, moving away from structural markers to functional and patient-centered outcomes. Effective interventions must involve early detection, personalized approaches, and interdisciplinary care, aiming to break the cycle of degeneration and improve patients' functional independence and quality of life. This review identifies the biomechanical, metabolic, and epigenetic "vicious cycles" that drive the comorbidity of sarcopenia and osteoarthritis. By integrating multi-omics data, digital twin modeling, and real-time biomechanical feedback, this work provides a framework for clinical precision medicine. The clinical significance lies in identifying a "mechanical window of opportunity" for early intervention-using personalized exercise and nutritional strategies to restore joint homeostasis and prevent irreversible functional decline.

11 September 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
XPXiuli Pu
Xiuli Pu
BCBuyun Chen
Buyun Chen
QLQiang Li
Qiang Li
CCChen Chen
Chen Chen
XWXinling Wang
Xinling Wang
In this work, a P(AAsp-AGlu)/PAADA Janus hydrogel patch is reported with excellent mechanical strength (around 410 kPa), prominent adhesion properties (over 550 J m−2) and repeatable adhesion (less than 20% decreasing after 5 adhesion cycles).

2 January 2025 in Burns & Trauma
Verified
Journal Article
Open access
SLShan Liu
Shan Liu
RWRenwen Wan
Renwen Wan
QLQingRong Li
QingRong Li
YCYisheng Chen
Yisheng Chen
YHYanwei He
Yanwei He
CCChen Chen
Chen Chen
Objective: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that significantly impairs muscle regeneration following injuries, contributing to numerous complications and reduced quality of life. There is an urgent need for therapeutic strategies that can enhance muscle regeneration and alleviate these pathological mechanisms. In this study, we evaluate the therapeutic efficacy of W-GA nanodots, which are composed of gallic acid (GA) and tungstate (W6+), on muscle regeneration in type 2 diabetes mellitus (T2D)-induced muscle injury, with a focus on their anti-inflammatory and antioxidative effects. Methods: This study synthesized ultrasmall W-GA nanodots that were optimized for improved stability and bioactivity under physiological conditions. In vitro assessments included cell viability, apoptosis, reactive oxygen species (ROS) generation, and myotube differentiation in C2C12 myoblasts under hyperglycemic conditions. In vivo, T2D was induced in C57BL/6 mice, followed by muscle injury and treatment with W-GA. Muscle repair, fibrosis, and functional recovery were assessed through histological analysis and gait analysis using the CatWalk system. Results: The W-GA nanodots significantly enhanced muscle cell proliferation, decreased ROS, and reduced apoptosis in vitro. In vivo, compared with the control group, the W-GA-treated group exhibited notably improved muscle regeneration, decreased fibrosis, and enhanced functional recovery. The treatment notably modulated the inflammatory response and oxidative stress in diabetic muscle tissues, facilitating improved regenerative dynamics and muscle function. Conclusions: W-GA nanodots effectively counter the pathological mechanisms of diabetic myopathy by enhancing regenerative capacity and reducing oxidative stress and inflammation. This nanomedicine approach offers a promising therapeutic avenue for improving muscle health and overall quality of life in individuals suffering from T2D. However, further studies are needed to explore the clinical applications and long-term efficacy of these nanodots in preventing diabetic complications.